NetworkNewsBreaks

TuesdayJan 17, 2017 2:46 pm

NetworkNewsBreaks – Alcobra (NASDAQ: ADHD) Shares Plunge on Disappointing Results of MDX Clinical Trial

Shares of Alcobra (NASDAQ: ADHD) slumped 49% today after the company reported top-line results from MEASURE, its second phase 3 clinical trial for the investigational product Metadoxine Extended Release (MDX) for the treatment of ADHD in adult patients. MDX did not meet the primary endpoint of demonstrating a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS). "We are exceedingly disappointed with these top-line results. In the coming weeks, the Company intends to review the full data set from MEASURE. Consequently, we will evaluate our options and…

Continue Reading

TuesdayJan 17, 2017 2:05 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 17, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PULM 135.33% – News: PUR1900 obtains Qualified Infectious Disease Product designation by FDA OWCP 53.08% – News: Releases annual shareholders letter REXX 27.42% – News: Releases two-year financial and operational plan; provides financial update ITRO 25.19% – News: Ships first silver bullion produced by its e-scrap refining technology HTCO 23.33% – News: Introduces GrowLease: lease programs for its flagship of automated grow systems PME 13.67% – News: Declares Q1 2017 quarterly cash dividend CGIX…

Continue Reading

TuesdayJan 17, 2017 1:18 pm

NetworkNewsBreaks – Benitec (NASDAQ: BNTC) Shares Surge on Orphan Drug Designation for BB-301 in the EU

Benitec Biopharma (NASDAQ: BNTC; BNTCW) is trading 71% higher on news that the company’s BB-301 for the treatment of patients with oculopharyngeal muscular dystrophy (OPMD) has been granted Orphan Drug Designation by the European Commission. The designation, which provides regulatory and financial incentives including a 10-year period of marketing exclusivity in the EU after product approval and protocol assistance from the European Medicines Agency (EMA) during the product development phase, was based on favorable recommendation from the EMA Committee for Orphan Medicinal Products (COMP). Entry into the clinic with a phase I/II study in OPMD patients is anticipated in 2018,…

Continue Reading

TuesdayJan 17, 2017 12:17 pm

NetworkNewsBreaks – Gevo, Inc. (NASDAQ: GEVO) Receives EPA Pathway Approval for Isobutanol as Advanced Biofuel

Gevo (NASDAQ: GEVO) this morning said it has received EPA approval for the pathway for isobutanol to be an advanced biofuel under the Renewable Fuel Standard Program (RFS). This development presents an opportunity for Gevo to achieve the 50% or greater greenhouse gas emissions reduction needed to claim the advanced D5 Renewable Identification Number (RIN). Gevo’s isobutanol currently generates D6 RINs, and with this approval, it could generate D5 RINs as well, which have historically had greater value in the marketplace. “We are pleased that there is now a route for advanced fuels that provides protein that contributes to the…

Continue Reading

TuesdayJan 17, 2017 12:15 pm

NetworkNewsBreaks – Celsion (NASDAQ: CLSN) Shares Hike on Positive Data from the OVATION Study

Shares of Celsion (NASDAQ: CLSN) are up 37% after the company reported positive data from the fourth cohort of patients in its phase Ib dose escalating clinical trial (the OVATION Study). The study combines GEN-1, the company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly diagnosed patients with stage III and IV ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. The study has produced significant results, with no dose limiting toxicities and promising efficacy signals in this difficult to treat cancer. Celsion said it expects to report final data in Q2…

Continue Reading

TuesdayJan 17, 2017 9:17 am

NetworkNewsBreaks – Amyris, Inc. (NASDAQ: AMRS) Making Technological Breakthroughs under Guidance of Highly Experienced Management

Amyris (NASDAQ: AMRS) is one of the fastest growing industrial biotechnology companies among the 2,772 in the U.S today. The company's eight-person management team is comprised of hand-picked individuals with a proven ability to innovate and build companies in a number of industries. With over 30 years of experience as a tech entrepreneur and thought leader, president and CEO John Melo has led Amyris from technology development and industrial startup to product development and final commercialization. Thanks to the team's level of experience, Amyris has made outstanding technological breakthroughs, among these is the world's leading treatment for malaria, saving over…

Continue Reading

FridayJan 13, 2017 2:51 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 13, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: TVIA 9.52% – News: Law firm issues alert for lead plaintiff deadline of January 17, 2017 TTNP 5.00% – News: Receives J-Code by CMS for Probuphine® Implant CBAK 3.00% – News: Changes company name to CBAK Energy Technology, Inc. DVAX 2.33% – News: Law firm issues alert for lead plaintiff deadline of January 17, 2017 CIIX 2.05% – News: Moving on momentum from recent announcement of new China-based headquarters for cannabidiol health products online…

Continue Reading

FridayJan 13, 2017 2:09 pm

NetworkNewsBreaks – Medical Transcription Billing, Corp. (NASDAQ: MTBC) Embraces Possible Obamacare Changes in Trump Presidency

Medical Transcription Billing (NASDAQ: MTBC) (NASDAQ: MTBCP) offers services that could actually become more sought-after following changes to health insurance laws. “There are concerns that if the Trump administration completely repeals Obamacare, this might remove the need for a series of services currently offered by healthcare technology companies, such as revenue cycle management or more comprehensive practice management solutions.” … “Medical Transcription Billing believes the exact opposite. The company’s management feels that it is very unlikely that the Trump administration and the Republican-led Congress will completely eliminate insurance for 25 million Americans. The more likely scenario is that the administration…

Continue Reading

FridayJan 13, 2017 2:03 pm

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Remains Steady in Position as O2O Service Leader; Anticipates Revenue Boost with Xinhua Game Channel

Moxian, Inc. (NASDAQ: MOXC) continues to position itself as a leader in the O2O service market and a competitive digital marketing company in China by presenting new platforms. “Launched as a joint effort with Xinhua New Media and aimed at further strengthening the company’s partnership with Xinhua New Media Culture Communication Co., Ltd., the game channel is expected to bring multiple benefits to the company, including higher revenue streams from advertisement sales and game downloads, as well as ultimately attracting new users for its own Moxian+ platform and app. The project can bring massive exposure to the company’s services, given…

Continue Reading

FridayJan 13, 2017 1:58 pm

NetworkNewsBreaks – Naked Brand Group, Inc. (NASDAQ: NAKD) Shares Skyrocket on LOI to Merge with Bendon Limited

Shares of Naked Brand Group (NASDAQ: NAKD) soared 173% following this morning’s announcement that the company has entered into a letter of intent for a proposed merger with Bendon Limited to create a portfolio of innerwear, sleepwear and swimwear brands. Per the agreement, Bendon gains immediate access to the U.S. market while Naked will be able to leverage Bendon’s well-established global distribution channels. Naked CEO Carol Hochman will serve as COO of the emerging company. “We are extremely excited about the potential of this proposed merger, and look forward to capitalizing on Bendon’s scale and expertise to further expand the…

Continue Reading